Instil Bio TIL 深 滬
已收盤 03-27 16:00:00 美东时间
7.79
-0.570
-6.82%
華盛通- 最 高8.36
- 今 開8.36
- 成交量 7.27万股
- 最 低 7.5101
- 昨 收 8.36
- 總市值 5283.16万
- 52周最高 42.79
- 市盈率 靜 --
- 換手率 1.07%
- 52周最低 5.67
- 委 比 -78.57%
- 總股本 678.20万
- 歷史最高 589.80
- 量 比 3.82
- 振 幅 10.17%
- 歷史最低 0.80
- 每 手 1
- 風險率 7.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Instil Bio Q4 net loss per share narrows
Instil Bio Q4 net loss per share narrows Overview U.S. biotechnology firm's Q4 net loss per share narrowed from prior year Company ended 2025 with $76.3 mln in cash and marketable securities, expects runway beyond 2027 Instil discontinued AXN-2510 development, now pursuing acquisitions and in-licens
03-27 19:09
Instil Bio Q4 Adj. EPS $(0.97) Beats $(2.03) Estimate
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(2.03) by 52.15 percent. This is a 10.19 percent increase over losses of $(1.08) per share from the
03-27 19:08
Instil Bio FY2025 operating loss widens 6.85% to $(78.6) million; revenue rises 110.17% to $9.0 million
Instil Bio FY2025 operating loss widens 6.85% to $(78.6) million; revenue rises 110.17% to $9.0 million Instil Bio published an annual report on Form 10-K with full-year financial results, reporting a net loss of USD 71.4 million. Total operating expenses were USD 78.6 million, including research an
03-27 19:07
Instil Bio Non-GAAP EPS of -$0.97 beats by $2.81
Instil Bio press release (TIL): Q4 Non-GAAP EPS of -$0.97 beats by $2.81. As of December 31, 2025, Instil had $76.3 million in total cash, cash equivalents, restricted cash and marketable securities, ...
03-27 19:04
BRIEF-Instil Bio Q4 Basic EPS USD -1.21
BRIEF-Instil Bio Q4 Basic EPS USD -1.21 Mar 27 (Reuters) - Instil Bio Q4 net income USD -8.191 million.
03-27 19:00
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Instil Bio reported its FY2025 financial results with total cash of $76.3M as of Dec 31, 2025, and provided an update on strategic developments. The company discontinued the clinical development of AXN-2510 and is now focusing on external innovation through acquisitions and in-licensing opportunities in various therapeutic areas. Despite a net loss of $71.4M for the year, Instil believes its capital position will fund operations beyond 2027. The ...
03-27 11:00
核心管线不及预期？宜明昂科盘中跌超15%，创始人田文志：预期年底递交preBLA申请
本文来源：时代财经 作者：张羽岐 图片来源：图虫创意 1月21日，港股上市公司宜明昂科（01541.HK）盘中一度大跌超15%。消息面上，有市场传言称，因...
01-21 21:28
向“领跑者”跨越！ 中国双抗药物再迎高光时刻
炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ （来源：每日经济新闻） 每经记者：陈星 每经编辑：陈俊杰 2026年1月12日...
01-14 20:25
